Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Sponsor
Chong Kun Dang Pharmaceutical
Study ID
NCT07365358
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Diabete Type 2

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • empagliflozin 10mg — DRUG
    once a day for 24 weeks
  • Glimepiride 1mg — DRUG
    once a day for 24 weeks

Study Details

The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Key Dates

Start date
Mar 31, 2026
Status verified
Jan 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Expermental group 1
    Empamax® 10mg
  • Active Comparator: Expermental group 2
    Amaryl® 1mg

Primary Outcome Measure

Percentage of subjects who meet 3 conditions at the same time [ Time Frame: Baseline and Week 24 ]

Central Contacts

Related Studies